Relief Therapeutics Holding AG (RLFTF)

[ratna1]

Hi Elk! Have you seen this report on the progress of AMARIN with their drug VASCEPA for COVID19 patients?
Some pretty impressive results backed by Harvard Medical school:
https://www.uspharmacist.com/article/icosapent-ethyl-linked-to-decreased-inflammation-and-improved-covid19-symptoms

There are these other therapies out there based on icosapent ethyl ester (which is a molecule derived from Omega3 fatty acid) which has shown astounding efficacy in reducing strokes , heart attacks and diabetes related inflammation etc. and is now being tested by KAISER PERMANENTE for it's effects on COVID on some 15.000 CVD patients that are already receiving VASCEPA for their cardiological condition

By the time RELIEF is moving on this, the new standard of care replacing REMDESIVIR may well be VASCEPA even so AVIPTADIL is way ahead up to now...

I have been pondering wether there might be a way for a (yet to be formed)share- /stake-holder group to reach out to Dr. Javitt and try to engage him in a direct conversation with civility yet forthright?
Any ideas?